Journal of Cellular Biochemistry

NPY revealed as a critical modulator of osteoblast function in vitro: New insights into the role of Y1 and Y2 receptors

Authors

  • Liliana Teixeira,

    1. Instituto de Engenharia Biomédica (INEB), Divisão de Biomateriais, NewTherapies Group, Universidade do Porto, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal
    Search for more papers by this author
  • Daniela M. Sousa,

    1. Instituto de Engenharia Biomédica (INEB), Divisão de Biomateriais, NewTherapies Group, Universidade do Porto, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal
    Search for more papers by this author
  • Ana Filipa Nunes,

    1. Nerve regeneration group, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal
    2. iMed.UL, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
    Search for more papers by this author
  • Mónica M. Sousa,

    1. Nerve regeneration group, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal
    Search for more papers by this author
  • Herbert Herzog,

    1. Neuroscience Program, Garvan Institute of Medical Research, Sydney, Australia
    Search for more papers by this author
  • Meriem Lamghari

    Corresponding author
    1. Instituto de Engenharia Biomédica (INEB), Divisão de Biomateriais, NewTherapies Group, Universidade do Porto, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal
    • Instituto de Engenharia Biomédica (INEB), NewTherapies Group; Rua do Campo Alegre, 823, 4150-180 Porto, Portugal.
    Search for more papers by this author

Abstract

Neuropeptide Y (NPY) has recently emerged as a potential regulator of bone homeostasis. However, the relevance of NPY's role in osteoblast activity and the biological functions involving NPY receptors in bone homeostasis remain to be clarified. Here we report that chronically elevated NPY levels leaded to a modulation of the level of Y2 receptor expression marked with a transient down and upregulation according to the stage of osteoblast differentiation. We also show that NPY is a negative regulator of Y1 receptor expression. The pharmalogical activation of Y2 receptor with its agonist resulted in similar effect. Functional analysis also revealed the osteogenic potential of NPY with osteoblast phenotype markers being significantly enhanced in osteoprogenitor cells stimulated by NPY, probably due to the down-regulation of Y1 receptor. In contrasts, these cells exhibit a reduction in calcium deposition in extracellular matrix most likely mediated via Y2 receptor signalling. Furthermore, we show that NPY modulates receptor activator of nuclear factor kB (NF-kB) (RANK) ligand and osteoprotegerin, two key factors regulating bone remodelling. Specifically, NPY inhibits the transcriptional activity of RANKL promoter in osteoprogenitor cells and enhances OPG expression in osteoblasts at early stages of differentiation. However, NPY effect on OPG seemed to be unrelated to Y2 receptor activation. Taken together the present data supported the contribution of NPY pathway in bone homeostasis via a direct action on osteoblasts cells. J. Cell. Biochem. 107: 908–916, 2009. © 2009 Wiley-Liss, Inc.

Ancillary